

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sunho Biologics, Inc.

盛禾生物控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2898)

APPOINTMENT OF AUDITOR

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Sunho Biologics, Inc. (the “**Company**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Reference is made to the announcement of the Company dated 15 September 2025 in relation to the resignation of Deloitte Touche Tohmatsu (“**Deloitte**”) as the auditor of the Company (the “**Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

Prior to the resignation of Deloitte as the Auditor, the Audit Committee had obtained and reviewed audit proposals provided by Deloitte as well as other professional accounting firms, and considered a number of factors including but not limited to their respective industry experience, resource allocation and proposed fees for the year ending 31 December 2025. In view of the more competitive proposal provided by other professional accounting firms, the Board and the Audit Committee consider that the change of Auditor would enhance the cost-effectiveness of the audit of the Company.

The Board announces that, with the recommendation of the Audit Committee, it has resolved to appoint ZHONGHUI ANDA CPA Limited (“**Zhonghui Anda**”) as the new Auditor with effect from 16 September 2025 to fill the casual vacancy following the resignation of Deloitte and to hold office until the conclusion of the next annual general meeting of the Company.

After taking into account a number of factors, including but not limited to (i) the industry knowledge and technical competence of Zhonghui Anda and its extensive experience in handling audit work for companies listed on The Stock Exchange of Hong Kong Limited, and its familiarity with the requirements under the Listing Rules and IFRS Accounting Standards as issued by the International Accounting Standards Board; (ii) Zhonghui Anda’s audit proposal and proposed auditor’s remuneration; (iii) its resources and capabilities (including but not limited to in terms of manpower and time); (iv) its market reputation and

track record; and (v) the relevant guidelines issued by the Accounting and Financial Reporting Council, the Audit Committee assessed and considered Zhonghui Anda to be independent, eligible and suitable to act as the Auditor. The Board and the Audit Committee are of the view that the change of the Auditor is in the interest of the Company and the Shareholders as a whole.

The Board would like to express its warm welcome to Zhonghui Anda on its appointment as the new Auditor.

By order of the Board
Sunho Biologics, Inc.
Mr. ZHANG Feng
Chairman and executive Director

Hong Kong, 16 September 2025

As at the date of this announcement, the executive Directors are Mr. ZHANG Feng, Dr. YIN Liusong and Ms. JIANG Xiaoling; the non-executive Director is Mr. FAN Rongkui; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.